149 related articles for article (PubMed ID: 38878767)
1. Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen.
Valdivielso P; Coca Prieto I
Med; 2024 Jun; 5(6):493-494. PubMed ID: 38878767
[TBL] [Abstract][Full Text] [Related]
2. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
Stroes ESG; Alexander VJ; Karwatowska-Prokopczuk E; Hegele RA; Arca M; Ballantyne CM; Soran H; Prohaska TA; Xia S; Ginsberg HN; Witztum JL; Tsimikas S;
N Engl J Med; 2024 May; 390(19):1781-1792. PubMed ID: 38587247
[TBL] [Abstract][Full Text] [Related]
3. Targeting APOC3 in the familial chylomicronemia syndrome.
Gaudet D; Brisson D; Tremblay K; Alexander VJ; Singleton W; Hughes SG; Geary RS; Baker BF; Graham MJ; Crooke RM; Witztum JL
N Engl J Med; 2014 Dec; 371(23):2200-6. PubMed ID: 25470695
[TBL] [Abstract][Full Text] [Related]
4. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Witztum JL; Gaudet D; Freedman SD; Alexander VJ; Digenio A; Williams KR; Yang Q; Hughes SG; Geary RS; Arca M; Stroes ESG; Bergeron J; Soran H; Civeira F; Hemphill L; Tsimikas S; Blom DJ; O'Dea L; Bruckert E
N Engl J Med; 2019 Aug; 381(6):531-542. PubMed ID: 31390500
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
6. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.
Yang X; Lee SR; Choi YS; Alexander VJ; Digenio A; Yang Q; Miller YI; Witztum JL; Tsimikas S
J Lipid Res; 2016 Apr; 57(4):706-13. PubMed ID: 26848137
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
[TBL] [Abstract][Full Text] [Related]
8. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment.
Gallo A; Béliard S; D'Erasmo L; Bruckert E
Curr Atheroscler Rep; 2020 Aug; 22(11):63. PubMed ID: 32852651
[TBL] [Abstract][Full Text] [Related]
9. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
10. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
Bergmark BA; Marston NA; Prohaska TA; Alexander VJ; Zimerman A; Moura FA; Murphy SA; Goodrich EL; Zhang S; Gaudet D; Karwatowska-Prokopczuk E; Tsimikas S; Giugliano RP; Sabatine MS;
N Engl J Med; 2024 May; 390(19):1770-1780. PubMed ID: 38587249
[TBL] [Abstract][Full Text] [Related]
11. Volanesorsen: First Global Approval.
Paik J; Duggan S
Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
Chaudhry R; Viljoen A; Wierzbicki AS
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
[TBL] [Abstract][Full Text] [Related]
13. Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen: A case report.
Tünnemann-Tarr A; Scharnagl H; Katzmann JL; Stürzebecher P; Laufs U
Medicine (Baltimore); 2021 Oct; 100(42):e27573. PubMed ID: 34678899
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies.
Dib I; Khalil A; Chouaib R; El-Makhour Y; Noureddine H
Mol Biol Rep; 2021 Jan; 48(1):875-886. PubMed ID: 33389539
[TBL] [Abstract][Full Text] [Related]
15. Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma.
Yamamoto T; Obika S; Nakatani M; Yasuhara H; Wada F; Shibata E; Shibata MA; Harada-Shiba M
Eur J Pharmacol; 2014 Jan; 723():353-9. PubMed ID: 24269597
[TBL] [Abstract][Full Text] [Related]
16. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy: Targeting apoc-III to lower triglycerides.
Huynh K
Nat Rev Cardiol; 2015 Feb; 12(2):64. PubMed ID: 25533798
[No Abstract] [Full Text] [Related]
18. Volanesorsen for treatment of familial chylomicronemia syndrome.
Lazarte J; Hegele RA
Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):685-693. PubMed ID: 34261380
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of therapies for chylomicronemia.
Shamsudeen I; Hegele RA
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):395-405. PubMed ID: 35762447
[TBL] [Abstract][Full Text] [Related]
20. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
Esan O; Wierzbicki AS
Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
